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Abstract
Background: Regional anticoagulation with citrate is the recommended first line treatment for patients receiving
continuous renal replacement therapy (CRRT). There is wide variability in filter patency which may be due to
differences in patient characteristics and local practice. It is also possible that citrate has effects on primary and
secondary haemostasis, fibrinolysis and platelet function that are still unknown. The primary aim of the study is to
describe the effect of citrate on coagulation and fibrinolysis pathways in both the patient and the haemodialysis
circuit.
Methods: The study will recruit 12 adult patients admitted to the intensive care unit, requiring CRRT with regional
citrate anticoagulation for acute kidney injury. Patients with pre-existing thrombotic or bleeding tendencies will be
excluded. Thrombin generation, clot lysis and platelet function will be measured at baseline and at 12, 24, 36, 48
and 72 h after commencing CRRT (from the patient and from the circuit). We will describe the evolution of
parameters over time as well as the differences in parameters between the patient and the circuit.
Discussion: The study will provide new data on the effects of citrate during continuous renal replacement therapy
which is not currently available. We will minimise confounding factors through the use of tight exclusion criteria
and accept that this will slow down recruitment. Depending on the results, we hope to incorporate the findings
into existing clinical guidelines and clinical practice with the aim to prevent premature filter clotting and
interruptions in treatment.
Trial registration: The study was registered with clinicaltrials.gov on 10th June 2015 (NCT02486614).
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Background
Citrate has emerged as the recommended first line anti-
coagulant for continuous renal replacement therapy
(CRRT) in the Intensive Care Unit (ICU) based on its effi-
cacy and safety profile [1]. It acts by chelating calcium and
inhibiting the blood coagulation chemistry at several levels
(Fig. 1). Several randomized controlled trials have shown
significantly longer filter patency with citrate compared to
anticoagulation with heparin [2]. However, the reported
circuit life with citrate anticoagulation varies from a mean
of 16 h to 125 h [2]. The exact reasons for this variation
are not clear but are likely to be multifactorial.
Patient characteristics and vascular access problems are
important risk factors for premature clotting. In fact, in
patients with acute kidney injury (AKI) and sepsis, the co-
agulation/fibrinolysis balance is often deranged even prior
to starting CRRT [3, 4]. A proportion of patients may also
have an underlying medical condition that predisposes
them to the formation of clots, such as Protein C defi-
ciency or anti-phospholipid syndrome. In addition, no
anticoagulant is effective at inhibiting all steps of the co-
agulation pathway completely. For instance, whilst citrate
reduces thrombin generation by inhibiting reactions up-
stream, it does not impact all effects of thrombin (Fig. 1).
It is also unknown whether citrate has any clinically im-
portant direct or indirect effects on fibrinolysis or platelet
function [5–7]. Finally, not all events within the circuit are
represented by systemic clotting results, and it has been
argued that coagulation and fibrinolysis need to be studied
separately in the patient and in the extracorporeal circuit
[8]. We report our protocol to study the effects of citrate




Our aim is to perform a detailed evaluation of the effects of
citrate on the coagulation and fibrinolysis pathways during
CRRT. The primary objective is to determine changes in
primary haemostasis, coagulation and fibrinolysis parame-
ters from baseline within the patient’s systemic circulation
and the CRRT circuit over the course of 72 h of re-
gional anticoagulation with citrate. The outcomes are
parameters reflecting the coagulation and fibrinolysis
pathways (see below).
Design
We plan to conduct a prospective observational cohort
study.
Setting
The study is conducted in the critical care unit in a ter-
tiary care centre in the United Kingdom.
Patient selection
Patients with AKI in whom the treating team intend to
commence on CRRT with citrate anti-coagulation will
be screened against the inclusion and exclusion criteria.
Patients meeting all of the inclusion criteria and none of
the exclusion criteria will be recruited.
The inclusion criteria are:
 admitted to the critical care unit
 treating clinician plans to initiate CRRT with regional
citrate anticoagulation
 age > 18 years
 expected to require CRRT for >72 h
Fig. 1 Known effects of citrate on clotting pathways
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 arterial or central venous catheter in situ to allow
blood sampling
Exclusion criteria are:
 known pre-existing thrombotic tendency
 known pre-existing bleeding tendency
 disseminated Intravascular Coagulation (DIC)
 transfusion of any blood products in the 24 h before
enrolment
 active bleeding (ie. needing blood transfusion) at
time of enrolment
 haemoglobin at time of enrolment <75 g/L
 haematocrit at time of enrolment >0.55 L/L
 patient would refuse red blood cell transfusion
(for example Jehova’s Witness)
 platelet count at time of enrolment <100 × 103/μL
 treatment with any anticoagulant or antiplatelet
agent at enrolment or within 7 days of enrolment
with the exception of heparin or low molecular
weight heparin for deep venous thromboembolism
(DVT) prophylaxis
 intravenous heparin exposure within 4 h of
commencing citrate anticoagulation
 malnourishment, ie. body mass index (BMI)
<18.5 kg/m2 or unplanned weight loss >10% actual
body weight (ABW) in preceding 6 months or BMI
<20 kg/m2 and unplanned weight loss >5% ABW in
preceding 6 months.
 CRRT prescribed for an indication other than acute
kidney injury
Sample size calculation
A formal sample size calculation was not possible due to
lack of data in the literature. Following discussion with
experts in the field, a sample size of 12 participants with
complete data for 48–72 h was considered to be ad-
equate to gain better understanding of coagulation and
fibrinolysis during citrate based CRRT and to inform the
design of future studies.
Blood sampling
Baseline
The following blood tests will be performed at base-
line, i.e. immediately prior to commencing CRRT: Full
Blood Count (FBC), prothrombin time (PT), activated
partial thromboplastin time ratio (APTTr), fibrinogen,
D-Dimers, antithrombin activity, protein C activity, free
protein S antigen, resistance to activated protein C (APCR)
screening, homocysteine, PT 20210 mutation test, factor
VIII activity, von Willebrand factor antigen, Dilute Russell’s
Viper Venom Time (DRVVT), Dilute Activated Partial
Thromboplastin Time (DAPTT), anticardiolipin antibodies,
anti-beta 2 glycoprotein I antibodies, thrombin generation
assay, clot lysis, prothrombin fragment 1 + 2, thrombin-
antithrombin complexes (TAT) enzyme linked immunoso-
bent assays (ELISA) and platelet function screening.
During CRRT
At 12, 24, 36, 48 and 72 h after commencing CRRT, blood
samples will be taken from the systemic circulation and
from the CRRT circuit to measure the following parame-
ters: FBC, PT, APTTr, fibrinogen, D-Dimers, thrombin
generation assay, clot lysis and platelet function screening.
Laboratory tests
All laboratory tests except FBC will be conducted in the
Haemostasis & Thrombosis Laboratories at Guy’s & St
Thomas’ Hospital. Dade® Innovin® recombinant thrombo-
plastin, Actin FS®, Thromboclotin®, Thrombin-Reagent®,
Innovance D-dimer and HYPHEN BioMed Biophen
FVIII:C chromogenic assay (Siemens Healthcare, Marburg,
Germany) will be used on Sysmex CS2100i coagulation
analysers (Sysmex UK, Milton Keynes, UK) for PT, APTT,
Clauss fibrinogen, D-dimers and FVIII activity respectively.
For lupus anticoagulant detection, DRVVT will employ
Life Diagnostics LA Screen and LA Confirm reagents
(Diagnostica Stago UK, Theale, UK), and DAPTT will use
Stago PTT-LA (Diagnostica Stago) in the screen and
addition of Bio/Data Corporation LA Confirmation Re-
agent (Alpha Labs, Eastleigh, UK) for the confirm. LA
assays will be performed on a Sysmex 2000i analyser
(Sysmex UK). Chromogenix Coamatic antithrombin,
Coamatic protein C, Coatest APC Resistance, Coatest
APCR resistance-V (Quadratech Diagnostic Ltd., Epsom,
UK) and STA®-Liatest® Free protein S (Diagnostica Stago)
will be used on Sysmex CS2000i analysers for antithrom-
bin activity, protein C activity, phenotypic activated pro-
tein C resistance and free protein S antigen respectively.
Inova Diagnostics QUANTA Lite® (ELISA) kits for IgG
and IgM anticardiolipin and anti-β2 glycoprotein I anti-
bodies (Werfen UK, Warrington, UK), Enzygnost® F1 + 2
and TAT will be performed on a Dynex DS2 ELISA
analyser (Werfen UK) for anticardiolipin antibodies, anti-
β2 glycoprotein I antibodies, prothrombin fragment 1 + 2
and thrombin-antithrombin complexes respectively.
HemosIL VWF Antigen will be performed on an
ACL TOP 500 coagulation analyser (Werfen UK) for
von Willebrand factor antigen. Platelet function
screening will be performed on a PFA-100 analyser
(Sysmex UK) with collagen/ADP and collagen/epi-
nephrine cartridges (Sysmex UK). Homocysteine will
be assayed with Abbott ARCHITECT chemilumines-
cent microparticle assay (Abbott UK, Maidenhead,
UK) on an Abbott ARCHITECT i2000SR immuno-
assay analyser (Abbott UK). The Thrombin Generation
Assay will performed using a Technoclone kit (Techno-
clone, Vienna, Austria) on a Wallac Victor3 multilabel plate
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reader (Perkin Elmer, Turku, Finland). The Clot Lysis
Assay will be performed as previously described [6]
and read on a Wallac Victor3 multilabel plate reader
(Perkin Elmer, Turku, Finland). The Prothrombin 20,210
polymorphism will be screened for using an in house de-
veloped allelic discrimination assay on an Applied Biosys-
tems 7500 Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA).
Baseline data collection
The following data will be collected: age, gender, ethni-
city, admission diagnosis, comorbidities, biochemistry
profile, C-reactive protein (CRP), Acute Physiology and
Chronic Health Evaluation (APACHE) II score on ad-
mission and daily Sequential Organ Failure Assessment
(SOFA) scores.
Withdrawal criteria
Patients will be excluded from the study at their own re-
quest or the request of their legal representative. They will
be excluded from further blood sampling if any of the
following events occur during the 72 h sampling period:
 Development of Disseminated Intravascular
Coagulation (DIC).
 Need for treatment with any systemic anticoagulant
or antiplatelet agent with the exception of heparin
or low molecular weight heparin for DVT
prophylaxis
 Need for treatment with platelets or clotting factors
Statistical analysis
The baseline characteristics will be summarised using
appropriate descriptive statistics [i.e. frequency (percent-
age) for categorical data and mean (standard deviation)
or median (interquartile range) for continuous data]. All
coagulation and fibrinolysis parameters at baseline will
be summarised as means (standard deviation) unless the
distribution is highlight skewed, in which case median
values (interquartile range) will be used.
Average coagulation and fibrinolysis parameters at
each time point, and the mean (standard deviation) of
the difference relative to baseline will be presented. The
evolution of parameters will also be illustrated graphic-
ally by plotting the mean (with 95% confidence interval)
against time points. Trajectories of individual patients
over time will be shown graphically. Separate figures will
be used to summarise data obtained from bloods taken
from the patient and that from the CRRT circuit.
Repeated measures analysis of variance (ANOVA) (one
for each of the parameters obtained from patient’s
bloods and separately for those from the circuit), will be
used to further explore changes in parameters over time.
Where CRRT ends before 72 h patients will not have
measurements taken at 72 h. The ANOVA will therefore
include all measurements up to 48 h (unless all patients
have complete data to 72 h, in which case the final time
point will also be included). If a main effect of time is
identified, post-hoc comparisons will be carried out to
determine where differences lie.
Coagulation and fibrinolysis parameters from the pa-
tients’ blood will be plotted against the corresponding
value obtained from blood drawn from the CRRT circuit.
The mean (standard deviation) of the differences will be
calculated overall and at each time point and Bland-
Altman limits of agreement calculated.
Discussion
To our best knowledge, this is the first study that will pro-
vide a detailed description of clotting and fibrinolysis pro-
cesses before CRRT and the effects of citrate on coagulation
pathways, fibrinolysis and platelet function during CRRT.
The strengths of this project are:
i) The project will provide data that are currently not
available.
ii) By using very tight inclusion and exclusion criteria
we are minimising confounding influences as much
as possible.
iii)Serial blood samples will be taken from the systemic
circulation and the CRRT circuit separately to
differentiate between events in the patient and in the
extracorporeal circuit.
iv) The results have potential to inform the design of
future exploratory studies and intervention trials
aimed a prolonging circuit life during CRRT and
preventing unplanned interruptions in treatment.
We are aware of potential limitations and risks of the
project which we will eliminate as much as possible.
i) As a result of very strict criteria for inclusion,
exclusion and withdrawal and a relatively long
sampling period, recruitment is likely to be slow.
It is possible that we identify medical problems
through this research that may have implications for
patients and their close relatives, for instance a genetic
predisposition to clotting which was previously not
known about. With approval by the Research Ethics
Committee, we have put measures in place to make
sure that affected patients and relatives will receive the
necessary medical attention.
Depending on the findings of the study, we plan to in-
corporate the results into current guidelines and clinical
practice and hope that premature filter clotting can be
prevented and the delivery of CRRT improves.
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